TNFRSF17 and Miyoshi myopathy: With the same rationale, a phase 1 dose-escalating study of JNJ-5322, an IgG1 tri-specific antibody that binds to CD3 on T cells and BCMA and GPRC5D on MM cells, is ongoing in patients with RRMM (NCT05652335).